Evaluating sleep quality in prostate and breast cancer patients undergoing hormonal treatment
Official title: SIESTA: A Pilot Observational Study to Investigate and Evaluate Sleep Quality in Cancer Patients Undergoing Hormonal Therapeutic Approaches: 1) Localized, Locally Advanced or Metastatic Prostate Cancer Receiving Treatment Including Androgen Deprivation Therapy 2) Full-resected Early (Stage I-III) Breast Cancer, Ductal Carcinoma in Situ or Lobular Carcinoma in Situ, Without Evidence of Residual Disease; Proven Postmenopausal Status
Run by Oncology Institute of Southern Switzerland · NCT04543799 · Data updated 2026-11-12
This study is trying to see how hormonal treatments affect sleep quality in people with prostate and breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Oncology Institute of Southern Switzerland Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Bellinzona) |
| Status | Recruiting |
| Started | September 24, 2020 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | November 18, 2025 |
| Trial ID | NCT04543799 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adult males over 18 with hormone-sensitive prostate cancer scheduled for androgen deprivation therapy and patients with fully resected early-stage breast cancer.
✕Probably not a fit
Patients with small cell prostate cancer or those not scheduled for hormonal therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess sleep quality in patients with localized, locally advanced, or metastatic hormone-sensitive prostate cancer and those with fully resected early-stage breast cancer. It will utilize polysomnography, questionnaires, actigraphy, and salivary melatonin samples to gather data on sleep patterns before and during hormonal therapies. Measurements will be taken at baseline, 6 months, and 12 months to compare sleep quality across different treatment groups. The study seeks to identify potential negative impacts of hormonal therapies on sleep and provide a foundation for future interventional trials.
Why it matters
Potential benefit: If successful, this study could lead to improved management of sleep quality in cancer patients undergoing hormonal treatments.
How similar studies have gone: While this approach is novel in its methodology, previous studies have indicated that hormonal treatments can affect sleep quality, suggesting potential relevance.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria for prostate cancer patients: * Written infor med consent according to International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures * Histologically proven adenocarcinoma of the prostate * Eastern Cooperative Oncology Group performance status 0-2 * Adult male patient \> 18 years of age, no upper age limit * Localized prostate cancer, locally advanced hormone-sensitive prostate cancer (HSPC) or metastatic hormone-sensitive prostate cancer (mHSPC) * ADT recipients are required to be scheduled to start ADT as standard of care (SOC) for metastatic or locally advanced prostate cancer * Scheduled to receive ADT treatment as SOC for \> 6 months in combination with radiotherapy or oral AR-targeted systemic treatment as prescribed by the treating physician or radiotherapy alone Exclusion Criteria for prostate cancer patients: * Histology with predominant small cell prostate cancer * Any previous treatment with ADT or oral AR-targeted agent (exception for short course anti-androgens - disease flare) * Have not received systemic treatment for any other cancer within the last 12 months * Active secondary malignancy that requires systemic therapy * Any clear contraindications present against treatment with ADT * Presence of sleep apnea syndrome, Apnea Hypopnea Index (AHI) \>15 at baseline * Body mass index (BMI) \> 35 at baseline * Severe respiratory disorders (asthma, Chronic obstructive pulmonary disease) at baseline * Severe cardiovascular disease or severe cardiovascular event \< 6 months * History of stroke or other neurologic chronic illnesses \< 6 months * Have demonstrated impaired mental status * History of brain tumours, presence of brain metastases or previous cranial irradiation * Night shift workers * Excessive lifestyle: massive coffee intake at night, regular excessive cigarette and alcohol consumption in the evening * Unhealthy sleep hygiene * Nocturia (the urgent need to urinate more than 2 times during the main sleep period at night) at baseline * Present diagnosis of depression or psychiatric illness pharmacologically treated * Diagnosis of insomnia and chronic intake of hypnotic medication at baseline * Chronic intake of medications that are known to induce sleep disturbance (antihistamines of first generation, cortisone intake \> 25 mg/day) * Any diagnosed condition that causes known sleep disturbance Inclusion criteria for breast cancer patients * Written informed consent according to International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures * Women with full-resected early (stage I-III) epithelial BC, ductal carcinoma in situ or lobular carcinoma in situ, without evidence of residual disease * Eastern Cooperative Oncology Group performance status 0-2 * Adult female patient ≥ 18 years of age, no upper age limit * Proven postmenopausal status (defined by absence of menstruation for at least 6 months and/or level of estradiol \<40 pg/ml, or bilateral oophorectomy or ovarian irradiation for suppression of ovarian function) Exclusion criteria for breast cancer patients * Non-epithelial BC or BC with mixed epithelial and non-epithelial histology * Previous chemotherapy at any time, in treatment with ET at not standard dosage * Have received systemic treatment for any other cancer within the last 12 months * Active secondary malignancy that requires systemic therapy * Presence of sleep apnea syndrome, Apnea Hypopnea Index (AHI) \>15 at baseline * Body mass index (BMI) \> 35 at baseline * Severe respiratory disorders (asthma, Chronic obstructive pulmonary disease) at baseline * Severe cardiovascular disease or severe cardiovascular event \< 6 months * History of stroke or other neurologic chronic illnesses \< 6 months * Have demonstrated impaired mental status * History of brain tumours, presence of brain metastases or previous cranial irradiation * Night shift workers * Excessive lifestyle: massive coffee intake at night, regular excessive cigarette and alcohol consumption in the evening * Unhealthy sleep hygiene * Nocturia (the urgent need to urinate more than 2 times during the main sleep period at night) at baseline * Present diagnosis of depression or psychiatric illness pharmacologically treated * Diagnosis of insomnia and chronic intake of hypnotic medication at baseline * Chronic intake of medications that are known to induce sleep disturbance (antihistamines of first generation, cortisone intake \> 25 mg/day) or any diagnosed condition that causes known sleep disturbance
Where it's running
-
Iosi
Bellinzona, Switzerland Recruiting
Study contacts
- Study coordinator: Ursula Vogl, MD
- Email: ursula.vogl@eoc.ch
- Phone: +419181113308463
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted radiopharmaceuticals for GRPR-positive cancers in adults
A phase 1 study tests two targeted radiopharmaceuticals, radiolabeled Lu-177 and Ac-225 compounds, to treat GRPR-expressing breast, prostate, colorectal, and other solid tumors in adults who have not benefited from standard therapies.
-
HER2 FPBMC therapy for metastatic breast and prostate cancer
This study tests whether infusing patients with their own immune cells, armed with a HER2-targeting antibody, can help treat metastatic breast or prostate cancer.
-
Digital app to support oncologist‑initiated genetic testing
This project tests a digital app (GA‑Mainstream) to help oncologists offer germline genetic testing to adults with breast, prostate, colon, or other GI cancers.
-
OCT-598 for advanced solid tumors
This trial tests whether OCT-598, by itself or with docetaxel, is safe and to find the best dose for adults with advanced solid tumors who have limited standard treatment options.
-
Axelopran for adults with advanced breast, lung, pancreas, or prostate cancer who take opioids
This trial will test whether taking axelopran can slow tumor progression, help bowel problems, and reduce inflammation in adults with advanced breast, lung, pancreas, or prostate cancer who are using opioid pain medicines.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.